First Report of Successful Rituximab Therapy in Idiopathic Sclerosing Mesenteritis.

Abstract

Sclerosing mesenteritis (SM) is a rare idiopathic fibroinflammatory disorder of the bowel mesentery adipose tissue. While the use of rituximab has been documented in IgG4-related SM, its effectiveness in idiopathic, IgG4-unrelated SM remains unknown. We present a case of idiopathic SM successfully managed with rituximab, suggesting that this treatment may be an option for patients who either have contraindications to or have not responded to current first-line therapies.